GLP-1 COST 2026: PILLS, SHOTS, COMPOUNDED, AND WHAT EACH REALLY COSTS

The short version of GLP-1 cost 2026: brand-name self-pay prices run from $149 a month for the lowest-dose pills to $449 a month for higher-dose Zepbound. Medicare's new GLP-1 Bridge charges eligible Part D enrollees $50 a month. Compounded programs such as GLP-1 weight loss at Hartwater Wellness cost $299 or $499 a month with provider care included. The brand prices cover the medication only. Several of them change after December 31, 2026, so compare what each price includes before you choose.
By Elaine Burris, APRN, FNP-C, Wellness Nurse Practitioner, Hartwater Wellness
Medically reviewed by Scott Bradley Burris, MD, Medical Director and board-certified anesthesiologist. Reviewed November 2026.
THE SHORT ANSWER
Pills: the Wegovy pill and Foundayo both start at $149 a month and top out at $299 to $349 a month for the highest doses.
Weekly shots: Wegovy is $349 a month after a two-month $199 introductory price; Zepbound is $299 to $449 a month depending on dose.
Medicare: eligible Part D enrollees can get Wegovy, Zepbound, or Foundayo for $50 a month through December 31, 2027.
Compounded: $299 a month for semaglutide and $499 for tirzepatide at Hartwater, with visits, lab monitoring, body composition scans, and home delivery included. Compounded drugs are not FDA-approved.
The 2026 rules: the shortages are over, and the FDA has tightened what compounders may make and how telehealth companies may market it.
GLP-1 COST 2026: SELF-PAY PRICES BY OPTION
Every GLP-1 cost 2026 figure below comes from the manufacturer's own self-pay page or our live GLP-1 page and was checked on the date in the caption. A "month" is four weeks for the injections and 30 days for the pills.
Ozempic, which is approved for type 2 diabetes, lists $349 a month for the 0.25 to 1 mg doses and $499 for 2 mg on TrumpRx. Prescribing it for weight loss alone is off-label. Wegovy is the same medicine, approved at higher doses for weight management.
WHAT THE SELF-PAY PRICE COVERS
A manufacturer self-pay price buys the medication. You still need a prescriber, dose adjustments during titration, and monitoring, which telehealth services and clinics charge for separately. Insurance does not count self-pay purchases toward your deductible.
A year of maintenance therapy at today's prices, medication only:
Wegovy 2.4 mg: 13 four-week fills at $349, about $4,540 a year.
Zepbound 10 or 15 mg: 13 four-week fills at $449 with on-time refills, about $5,840 a year. A late refill raises that month to $699.
Wegovy pill 25 mg or Foundayo 9 mg: 12 fills at $299, about $3,590 a year.
At Hartwater Wellness, compounded semaglutide is $299 a month and compounded tirzepatide is $499 a month at any dose, about $3,590 and $5,990 a year, with the clinical program included. If you choose a branded medication with us, you buy it at manufacturer pricing, and the clinical program is the same. Ask at your consultation what the program costs alongside a branded prescription.
The brand prices have expiration dates. Novo Nordisk says its self-pay pricing will be updated after December 31, 2026, and Lilly's savings cards and temporary Foundayo price cuts end the same day. We will update this table when the 2027 prices post.
TRUMPRX AND THE MEDICARE GLP-1 BRIDGE
TrumpRx.gov, the federal site launched in February 2026, lists the same manufacturer self-pay prices and links you to the manufacturer's pharmacy to fill. On October 28, 2026, it showed the Wegovy pill from $149, the Wegovy pen and Ozempic from $199 (the introductory price), and Zepbound from $299. It is a portal to those prices; the price itself is the same as buying direct.
The Medicare GLP-1 Bridge is a CMS demonstration that began July 1, 2026 and runs through December 31, 2027. Eligible people with Medicare Part D pay $50 for a monthly supply of certain GLP-1 medications for weight management, which the manufacturers list as Wegovy, Zepbound, and Foundayo. Eligibility rules apply, and the prescriber must request approval. Hartwater Wellness is a cash-pay practice and does not bill Medicare, so if you have Part D, ask about the Bridge before paying cash for a branded drug.
PILL OR SHOT
Two GLP-1 pills are now approved for weight management: the Wegovy pill (oral semaglutide, approved December 22, 2025) and Foundayo (orforglipron, approved April 1, 2026). In its approval trial, the Wegovy pill produced average weight loss of 16.6% at 64 weeks, close to the injection. Pills suit people who dislike needles and cost less at the top dose. They are taken every day. Each has its own instructions about timing with food and water. The weekly shots, especially tirzepatide (Zepbound), still produce the largest average weight loss.
The choice depends on your goals, your side effects, your budget, and how you take medications day to day. Pills also matter for maintenance after you reach your goal, the subject of our December 15 post on stopping a GLP-1.
COMPOUNDED GLP-1S: THE 2026 RULES IN PLAIN ENGLISH
Compounding means a licensed pharmacy prepares a medication for an individual patient's prescription. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness. They are prepared by licensed pharmacies under USP <797> sterile compounding standards, and they are not generic versions of branded drugs. Here is what changed, in order:
The shortages ended. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. The grace periods for state-licensed pharmacies ended February 18 and April 22, 2025, and for outsourcing facilities on March 19 and May 22, 2025. While a drug is in shortage, pharmacies may compound copies of it; once the shortage ends, they generally may not.
February 6, 2026: the FDA announced it would act against non-approved GLP-1 drugs mass-marketed as alternatives to approved products, including restricting the active ingredients used to make them.
March 3, 2026: the FDA announced warning letters to 30 telehealth companies for marketing compounded GLP-1s as if they were the same as approved drugs, or for hiding who actually made them.
April 1, 2026: the FDA restated when a compounded drug counts as "essentially a copy" of an approved one: the same active ingredient at the same or a similar strength, used the same way. Its example was semaglutide combined with vitamin B12. Adding an ingredient does not by itself make a compounded product different. A product is treated as distinct when the prescriber determines and documents a change that makes a significant difference for an identified individual patient.
May 1, 2026: the FDA proposed removing semaglutide, tirzepatide, and liraglutide from consideration for large-batch compounding by outsourcing facilities (the 503B bulks list). The comment period closed July 30, 2026. As of October 28, 2026, no final decision had been published. The proposal does not address state-licensed 503A pharmacies directly.
WHY ADDITIVE SELECTION IS A CLINICAL DECISION
Hartwater Wellness prescribes compounded semaglutide and tirzepatide from licensed Texas 503A compounding pharmacies, each prepared for one patient's prescription. Each formulation includes one additive, chosen for that patient: vitamin B6 (pyridoxine), vitamin B12 as cyanocobalamin or methylcobalamin, or L-carnitine.
The choice follows your history. A patient who had nausea on an earlier weight-loss medication, a patient with fatigue during a calorie deficit, and a patient with a known methylation variant may each receive a different formulation. Your provider records the reason for the choice in your chart and reviews it at follow-up visits. That patient-specific, documented decision is the standard the FDA's April 2026 guidance describes. If a patient has no documented reason for an additive, an FDA-approved medication is the straightforward choice, and we prescribe those too.
WHAT HARTWATER'S MONTHLY PRICE INCLUDES
The $299 (semaglutide) and $499 (tirzepatide) monthly prices are flat at every dose and include:
Your initial consultation and full evaluation with our providers
A personalized dosing plan, with monthly provider oversight and adjustments
Lab monitoring and InBody 970S body composition scans, which show how much of your loss is fat and how much is lean mass (see post #6 on muscle loss on GLP-1)
Medication shipped to your home, and topical numbing for injection sites
New patients place a $100 consultation deposit, which applies to anything purchased at that first visit. The patient experience page walks through the visit. Hartwater Wellness is a cash-pay practice; HSA and FSA accepted.
FREQUENTLY ASKED QUESTIONS
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It contains the same active ingredient. A compounded preparation is not FDA-approved, is not a generic, and has not been evaluated by the FDA for safety or effectiveness. It is prepared by a licensed pharmacy for an individual prescription and may differ in concentration and added ingredients.
Can you still get compounded semaglutide in 2026?
Yes, under narrower conditions. Since the shortages ended, pharmacies generally may not compound copies of the approved drugs. A compounded GLP-1 must reflect a documented, patient-specific clinical difference, or fall within the small volume the FDA has said it will not act on.
Is the Wegovy pill cheaper than the Wegovy shot?
At most doses, yes. The Wegovy pill is $149 to $299 a month by dose, and the Wegovy pen is $349 a month after the introductory offer. Both prices are scheduled for review after December 31, 2026.
How much do GLP-1s cost with Medicare in 2026?
Through the Medicare GLP-1 Bridge, eligible Part D enrollees pay $50 a month for certain weight-loss GLP-1s from July 1, 2026 through December 31, 2027. Eligibility rules apply, and your prescriber must request approval.
SCHEDULE A CONSULTATION
If you are weighing a pill, a shot, or a compounded program, a consultation is the place to compare them against your history, your goals, and your budget. Hartwater Wellness is a physician-led practice at 7200 West University Drive, Suite 170, in McKinney, serving Frisco, Allen, Prosper, Plano, Celina, and Collin County. Schedule online or call (469) 678-8748.
SOURCES
NovoCare Pharmacy, Wegovy self-pay offer (Wegovy pill and pen prices, Wegovy HD, introductory offer through December 31, 2026), checked October 28, 2026: https://www.novocare.com/pharmacy/wegovy/offer.html
Eli Lilly, Zepbound coverage and savings (KwikPen and vial self-pay prices, 45-day refill terms, savings end December 31, 2026), checked October 28, 2026: https://www.zepbound.lilly.com/coverage-savings
Eli Lilly, Foundayo coverage and savings (self-pay prices by dose, temporary reductions through December 31, 2026), checked October 28, 2026: https://foundayo.lilly.com/coverage-savings
TrumpRx.gov (listed prices for Wegovy pill, Wegovy, Ozempic, Zepbound), checked October 28, 2026: https://trumprx.gov/
Centers for Medicare & Medicaid Services, "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries" (May 6, 2026): https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries
Novo Nordisk, "Wegovy pill approved in the US as first oral GLP-1 for weight management" (December 22, 2025): https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472
U.S. Food and Drug Administration, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize" (shortage resolutions, grace periods, April 1, 2026 update): https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
U.S. Food and Drug Administration, "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs" (February 6, 2026): https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
U.S. Food and Drug Administration, warning letters to 30 telehealth companies on compounded GLP-1 marketing (March 3, 2026): https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (91 FR 23431, May 1, 2026): https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
Federal Register, Extension of Comment Period (91 FR 38719, June 26, 2026): https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
Hartwater Wellness, GLP-1 Weight Loss (monthly prices and inclusions), checked October 28, 2026: https://www.hartwaterwellness.com/glp-1-therapy-mckinney-tx
Hartwater Wellness, Financial Policy (consultation deposit): https://www.hartwaterwellness.com/financial-policy
.png)



